TY - JOUR
AU - Antone, Nicoleta
AB - Purpose of Review The majority of Central and Eastern European (CEE) countries report inferior breast cancer survival rates compared with Western European countries. We review limitations in access to screening programs, surgery, radiotherapy, pathology, palliative care, and antineoplastic medicines as potential explanations for these disparities. Recent Findings Most CEE countries do not have the quality and quantity of radiotherapy needed to adequately service the population. Surgical services are widely accessible, but sentinel node biopsy is not universally available. There are important limitations for CEE patients in accessing high-quality pathology. Many patients living with advanced cancer are in dire need of palliation services. Important inequalities exist in availability and patient costs, especially for newer, more expensive drugs, across Europe, while drug shortages affect several “essential,” old, and inexpensive drugs. Summary Improvements in radiotherapy, surgery, and pathology and access to medicines are needed, together with the provision of trained health care professionals. . . Keywords Breast cancer Eastern Europe Limited resources Background has a 5-year survival rate of 78.0% (CI 77.3–78.7), the rest of CEE countries have a 5-year survival rate of 10–15% lower Central and Eastern European (CEE) countries represent the than the European mean (81.8%, 95% CI 81.6–82.0) [1]. 
TI - Access to Affordable Breast Cancer Care in Eastern Europe
JF - Current Breast Cancer Reports
DO - 10.1007/s12609-018-0285-8
DA - 2018-08-10
UR - https://www.deepdyve.com/lp/springer-journals/access-to-affordable-breast-cancer-care-in-eastern-europe-m1JBZQTbaD
SP - 170
EP - 178
VL - 10
IS - 3
DP - DeepDyve
ER -